Eli Lilly and Company (LLY) Compounding Analysis | TGMCharts
Eli Lilly and Company (LLY) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 10YDoes not currently clear the 15%+, 20%+, or 30%+ revenue bars over 10Y.
Score
42/100
10Y CAGR
12.6%
Median YoY
8.4%
YoY volatility
σ 18.7pp· choppy
Quarters ≥ 20%
15 of 40
Negative quarters
8
Valuation vs own 10Y history
Latest historical P/S 13.5x · 10Y median 8.6x · 71st percentile · as of Oct 2, 2026
How this score is computed
Quarters at or above 20%: 15 of 40 → 15 of 40 pts
Steadiness (typical swing 18.7pp) → 11.6 of 25 pts
Pace (median 8.4% YoY) → 0 of 20 pts
Latest quarter (47.7% YoY) → 15 of 15 pts
Score: 42 of 100
Annualized revenue (TTM) · by quarter, last 40
tgmcharts.com
Quarterly YoY revenue growth vs the 20% line
tgmcharts.com
P/S multiple vs its 10Y median
tgmcharts.com
Across metrics · 10Y
LLY reported stats per metric over 10Y: annual CAGR, median quarterly year-over-year growth, YoY standard deviation, quarters at or above 20%, and negative quarters.
Metric
10Y CAGR
Median YoY
YoY σ
Qtrs ≥ 20%
Neg. qtrs
RevenueRevenue
12.6%
8.4%
18.7pp
15 of 40
8
EPSEPS
26.5%
21%
60.5pp
18 of 40
13
Op cash flowOperating cash flow
18.9%
18.3%
52.3pp
17 of 40
16
EBITDAEBITDA
20.2%
23%
31.3pp
23 of 40
8
FCFFree cash flow
21%
-15.5%
70.0pp
11 of 40
17
Reported figures over 10Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →